
EHA 2021 – Virtual

June 9-17, 2021





You are entering a medical section of the Pfizer Landing Page. All materials presented here are informative and they are not intended to be promotional.

Pfizer Oral Presentation

T Cell Re-directing Therapies in Relapsed/Refractory Multiple Myeloma

On Demand

Elranatamab (PF-06863135)

Abstract S192

MagnetisMM-1: Phase 1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma (MM)*

Costello CL

View Presentation

Pfizer ePosters

All Poster sessions will be available to attendees for on-demand viewing.

The Virtual Congress platform closes on August 15, 2021.

Acute Lymphoblastic Leukemia – Clinical

Inotuzumab EP353

A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (Pts) with B-cell precursor acute lymphoblastic leukemia (ALL) proceeding to hematopoietic stem cell transplant (HSCT)*

De Lima M

View Presentation

EP370 Inotuzumab

The patient experience of acute lymphoblastic leukemia and its treatment: a social media review

Morrison R

View Presentation

Chronic Myeloid Leukemia – Clinical

Bosutinib EP671

Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib*

Deininger M

View Presentation

Bosutinib EP672 Second-line bosutinib for patients with chronic phase chronic myeloid leukemia:

Final 10-year results of a phase 1/2 study* Gambacorti-Passerini C

View Presentation

Bosutinib EP684 The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients

with newly diagnosed chronic myeloid leukemia* Brummendorf T

View Presentation

Elranatamab (PF-06863135)

Myeloma and Other Monoclonal Gammopathies – Clinical

Overall, complete, and stringent complete response rates and minimal residual disease as

EP1025

potential surrogates for progression-free survival in newly diagnosed multiple myeloma Daniele P View Presentation

Elranatamab (PF-06863135)

refractory multiple myeloma

Overall and complete response rates as potential surrogates for overall survival in relapsed

EP1033

EP1175

PB1753

Daniele P View Presentation

Quality of Life, Palliative Care, Ethics and Health Economics

Quantifying patient preferences for tyrosine kinase inhibitors in chronic myeloid leukemia: a discrete-choice experiment*

Mason B View Presentation

AML

Bosutinib

Uncertainty about the future: insights from older patients with acute myeloid leukaemia

Publication Only

(AML) on different treatment paths Walter R

Bosutinib PB1520 Retrospective real-world comparison of clinical and economic burden between first-

generation and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)* Russell-Smith TA

Elranatamab (PF-06863135)

The impact of COVID-19 on patient disease experience: insights from social media posts

contributed Crawford R

The patient experience of multiple myeloma: symptoms and health-related quality of life Levy C

*Previously submitted abstract.

Elranatamab (PF-06863135)

PB1668

PB1667

Elranatamab (PF-06863135) PB1665

Lyall M

Multiple myeloma treatment decisions from the patient perspective